DiaMedica reports Q3 2026 results, trial milestones in FGR and stroke programs
The company finished enrolling the first two dose cohorts of its fetal growth restriction study and crossed 200 patients in its stroke trial, with interim data expected early 2027.
DiaMedica Therapeutics reported third-quarter 2026 results on November 12, 2026, alongside updates across its three clinical programs for DM199 in preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke.
In the investigator-sponsored Phase 2 FGR trial at Tygerberg Hospital in Cape Town, enrollment has been completed in the first two of three planned cohorts, consisting of 12 participants treated at the 5 µg/kg and 10 µg/kg dose levels.1 The company said this is the first clinical study of DM199 in patients with early-onset FGR.1 DiaMedica plans a virtual event on November 24, 2026 with maternal-fetal medicine specialists to present preliminary, interim topline results from the first two FGR cohorts along with discussion of the disease and the rationale for DM199.1
In the pivotal Phase 2/3 ReMEDy2 stroke trial (NCT05065216), enrollment has reached the prespecified threshold of 200 participants, after which an independent Data Safety Monitoring Board will conduct an interim analysis once the 200th participant completes a 90-day follow-up period.1 That board will evaluate whether to re-estimate sample size or stop for futility based on the proportion of participants achieving a modified Rankin Scale score of 0 or 1, with final enrollment ranging from 300 to 728 participants depending on the outcome.1 DiaMedica expects the interim analysis to conclude in the first quarter of 2027.1
On the preeclampsia program, DiaMedica said it is preparing to begin its open-label Phase 2 dose-finding study in early-onset preeclampsia following authorization from Health Canada granted in September 2026.1 Separately, the European Medicines Agency granted conditional authorization in October 2026 for the same study design, with full approval contingent on country-specific site and ethics submissions.1 In the U.S., the company is still working through FDA feedback on reproductive toxicity data needed for an IND filing, and said the in-life portion of a supporting rat study has been completed, with pharmacokinetic and pharmacologic results expected in the coming weeks before DiaMedica submits the package to FDA.1
On financing, DiaMedica held $34.9 million in cash, cash equivalents and short-term investments at the end of the third quarter, down from $59.9 million at the close of 2025.1 The company said this level of cash is expected to fund its planned clinical studies and operations into the fourth quarter of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.